Age: 26
Free Agency: 2028 (RFA)
Accrued Seasons: 0
  • 2025 Salary Cap Charge: $846,666 (0.26% of cap)
  • 2025 Cash Payout: $860,000 (0.30% of spending)
  • 2025 Cash to Cap Ratio: 1.02
  • Contract Value: $2,985,000 ($995,000 APY)
  • Fully Guaranteed Money: $20,000
  • Contract Ranking: 171/230 at IDL

Current Contract

(UDFA, signed 2025)
(📝: indicates contract trigger occuring during that year)
YearAgeBase SalaryProrated Signing BonusCap
Number
Cap %
Dead Money & Cap Savings
202526$840,000$6,666$846,6660.3%
202627$1,005,000$6,666$1,011,6660.3%
202728$1,120,000$6,668$1,126,6680.4%
Total$2,965,000$20,000$2,985,000

Cash Flows

- fully earned money
- unearned or partially earned money
$1M
$2M
$3M
202520262027
Cash Due$860,000$1,005,000$1,120,000
Running Cash$860,000$1,865,000$2,985,000
Career Earnings: $20,000
Career APY: $0
Potential Earnings: $2,985,000
Total Guarantees: $20,000
Largest Cash Payment: $1,120,000 (2027)
Largest Cap Number: $1,126,668 (2027)

Contract History

TeamContract TypeStatusYear SignedYrsTotalAPYGuaranteesAmount Earned% EarnedEffective APY
BrownsUDFAActive20253$2,985,000$995,000$20,000$20,0000.7%$0
Earnings By Team
TeamYrsSalaryAPYPaid on Cap% Paid on CapPaid as Dead Money% Paid as Dead Money
Browns0$20,000$0$00.0%$00.0%

Statistics

No statistics available.

Valuation Diamond

The diamond is a scatterplot graph that visualizes the relation of the player's APY (in green) and performance (in blue, as measured by OTC's Valuations) to the rest of the league at his position. To understand how to read the diamond, read this explainer.

OTC ValuationAPY
Regular$0$0
Injury Adjusted$0$0
test
OTC Valuation $3M $6.1M $9.1M $12.1M $15.2M APY $5.3M $10.6M $15.9M $21.2M $26.5M $5,714,000 $7,000,000

Weekly Valuation Trends

The chart below illustrates the trend of the player's weekly OTC Valuations (in blue) from the most recent season, using APY (in green) and, if applicable, cash that is due to the player in the next season (in red) as benchmarks. Weeks not plotted indicate that the player was inactive or on a bye.

To see interactive and more in-depth use of OTC Valuation data, subscribe to OTC Premium.